Home › Research › Prevention trials
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress
S-Y Li, X-Y Xie, D Liu, G-R Cheng, F-F Hu, D-Y Zeng, X-C Chen, L-F Jia et al.. The journal of prevention of Alzheimer's disease, 2024
Topic: Brain imaging, connectivity and assessment
Screening commenced in July 2022. Currently, 1,965 participants have been randomized into lifestyle intervention (n = 772) and control groups (n = 1,193). Both the intervention and control groups exhibited similar baseline characteristics. Several lifestyle and vascular risk factors were present, indicating a potential window of opportunity for intervention. The intervention will be completed by 2025. This project will contribute to the evaluation of the effectiveness and safety of intervention strategies in controlling AD risk and reducing clinical events, providing a basis for public health decision-making in China.
Key findings
- Currently, 1,965 participants have been randomized into lifestyle intervention (n = 772) and control groups (n = 1,193).
- Both the intervention and control groups exhibited similar baseline characteristics.
- Several lifestyle and vascular risk factors were present, indicating a potential window of opportunity for intervention.
- The intervention will be completed by 2025.
- This project will contribute to the evaluation of the effectiveness and safety of intervention strategies in controlling AD risk and reducing clinical events, providing a basis for public health decision-making in China.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designrandomized controlled trial
- Participants772
- Evidence strengthHigh
How this study scored 80/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 45 of the 56 points we could judge it on, which is 80 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 772 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38706275) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 45 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 45 of the 56 points we could judge it on is 80 out of 100. |
| Total | 80 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Li, S.-Y., Xie, X.-Y., Liu, D., Cheng, G.-R., Hu, F.-F., Zeng, D.-Y., et al. (2024). China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2024.63
Vancouver
Li S.-Y, Xie X.-Y, Liu D, Cheng G.-R, Hu F.-F, Zeng D.-Y, et al. China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress. The journal of prevention of Alzheimer's disease. 2024. doi:10.14283/jpad.2024.63. PMID: 38706275.
BibTeX
@article{li2024-38706275,
author = {Li, S-Y and Xie, X-Y and Liu, D and Cheng, G-R and Hu, F-F and Zeng, D-Y and Chen, X-C and Jia, L-F and others},
title = {{China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2024},
doi = {10.14283/jpad.2024.63},
pmid = {38706275},
url = {https://doi.org/10.14283/jpad.2024.63}
}
Related studies in Prevention trials
Also tagged “metabolic-syndrome”
304 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 304 tagged studies.